Last reviewed · How we verify
NCT07436416: EXO-RENAL2
Circulating and Urinary Exosomal miRNA as Predictors of Treatment Response in Advanced Kidney Cancer
NA trial testing Circulating and Urinary Exosomal miRNA Analysis in Renal Cell Carcinoma in 91 participants. Completed in 31 December 2024.
31 December 2022
Quick facts
| Lead sponsor | Institute of Oncology Ljubljana |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 91 |
| Start date | 1 March 2022 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Slovenia |
Drugs / interventions tested
- Circulating and Urinary Exosomal miRNA Analysis
Conditions studied
- Renal Cell Carcinoma — all drugs for Renal Cell Carcinoma →
Sponsor
Institute of Oncology Ljubljana
Who can join
18 and older, any sex, with Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study investigates the role of circulating and urinary exosomal microRNAs (miRNAs) as potential biomarkers for predicting response to systemic therapy in patients with advanced renal cell carcinoma. Patients receiving immune checkpoint inhibitors or targeted therapies are followed during the first 16 weeks of treatment. Blood and urine samples are collected at predefined time points for analysis of exosome-associated miRNAs. Imaging assessments are performed as part of routine clinical follow-up. The aim of the study is to identify exosomal miRNA profiles associated with treatment response and to support the development of non-invasive predictive biomarkers in advanced kidney cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07436416
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT07397611 — Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC · Phase 2 · recruiting
- NCT07195682 — A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) · Phase 1 · recruiting
- NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
- NCT07227402 — A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6 · Phase 3 · recruiting
- NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
Other Institute of Oncology Ljubljana trials
Trials by the same sponsor.
- NCT06923787 — Effect of Perioperative Intravenous Infusion of Lidocaine on the Postoperative Course and the Immune Response in Patient · Phase 2 · recruiting
- NCT07432399 — Effect of Perioperative Lidocaine or High-Dose Dexamethasone on Immune Response in Colon Cancer Surgery (PILDI Study) · Phase 2 · recruiting
- NCT06650423 — Adherence to Aromatase Inhibitors ± Abemaciclib Treatment in Patients With Early-stage HER2-negative Breast Cancer · recruiting
- NCT07420647 — Pilot Study of Individualized Treatment for Genitourinary Syndrome of Menopause in Women After Cancer Treatment · NA · active not recruiting
- NCT07416500 — BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07436416 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Institute of Oncology Ljubljana
- Last refreshed: 27 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07436416.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing